Nan Dai

Nan Dai

Auto-generated profile, based on publicly available information

Nan Dai

Cancer Center, Daping Hospital and Army Medical Center of PLA, Army Medical University, Chongqing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
XZXiaolong Zhao
Xiaolong Zhao
MLMengxia Li
Mengxia Li
XDXiaoyan Dai
Xiaoyan Dai
YYYuyin Yang
Yuyin Yang
YPYang Peng
Yang Peng
DWDong Wang
Dong Wang
Resistance to platinum‑based drugs, such as cisplatin (CDDP), has been one of the major factors adversely affecting the clinical prognosis of patients with advanced non‑small cell lung cancer (NSCLC). While it has been demonstrated that dysregulation of microRNAs (miRNAs) may contribute to cisplatin resistance in NSCLC, the underlying mechanisms remain largely unclear. In the present study, the effect of exosomal miR‑1273a on cisplatin sensitivity of NSCLC was investigated. Microarray analysis was conducted to analyze the miRNA expression profiles in exosomes isolated from A549 cells treated with or without CDDP, and miR‑1273a was found to be the most prominently downregulated miRNA in CDDP‑treated exosomes. Overexpression of miR‑1273a significantly increased the cytotoxicity of CDDP and induced apoptosis in A549 cells. Syndecan binding protein (SDCBP) was predicted to be a direct target of miR‑1273a by bioinformatics and was found to be downregulated by miR‑1273a in A549 cells. Furthermore, decreased plasma exosomal miR‑1273a and increased plasma SDCBP levels were found to be associated with worse therapeutic outcomes of patients with advanced NSCLC receiving platinum‑based chemotherapy. These findings suggest that miR‑1273a is closely associated with the development of cisplatin resistance and may serve as a potential prognostic biomarker and therapeutic target for NSCLC.

8 August 2022 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
DJDan Jian
Dan Jian
XLXianfeng Lu
Xianfeng Lu
DWDong Wang
Dong Wang
MLMengxia Li
Mengxia Li
YYYuxin Yang
Yuxin Yang
YFYan Feng
Yan Feng

5 February 2023 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
WRWen Rao
Wen Rao
LYLujie Yang
Lujie Yang
NDNan Dai
Nan Dai
LZLiang Zhang
Liang Zhang
JLJie Liu
Jie Liu
DWDong Wang
Dong Wang